Clinical Trial Detail

NCT ID NCT01606579
Title Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Prism Pharma Co., Ltd.
Indications

bone marrow cancer

chronic myeloid leukemia

acute myeloid leukemia

Therapies

Cytarabine + PRI-724

Dasatinib + PRI-724

PRI-724

Age Groups: adult

No variant requirements are available.